Get the Stockscreener App
59.43
0.17%
0.10
After Hours:
59.12
-0.31
-0.52%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $59.43, with a volume of 12.03M.
It is up +0.17% in the last 24 hours and up +16.03% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$59.33
Open:
$59.27
24h Volume:
12.03M
Relative Volume:
0.61
Market Cap:
$264.08B
Revenue:
$46.69B
Net Income/Loss:
$15.29B
P/E Ratio:
17.31
EPS:
3.4329
Net Cash Flow:
$9.25B
1W Performance:
-4.55%
1M Performance:
+16.03%
6M Performance:
+18.79%
1Y Performance:
-30.36%
1-Day Range:
$58.59
$59.91
1-Week Range:
$58.59
$63.99
52-Week Range:
$43.08
$93.80
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
59.43 | 263.63B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,037.15 | 916.62B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.25 | 547.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.01 | 389.58B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
148.68 | 285.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.27 | 268.90B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures - Finviz
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? - The Motley Fool
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? - Finviz
5 Stocks To Keep an Eye On in 2026, According to Experts - AOL.com
Novo Nordisk’s Wegovy Pill And Akero Deal Reframe Obesity Growth Story - Sahm
Market Trends: What is the next catalyst for ISPCRate Cut & Weekly Setup with ROI Potential - baoquankhu1.vn
Stock Report: Is Novo Nordisk A s b Shares Adrhedged in a consolidation phaseJuly 2025 Highlights & Real-Time Sentiment Analysis - baoquankhu1.vn
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Jim Cramer on Novo Nordisk: "I Think They're Making a Turn Here" - Finviz
Novo Nordisk ADR: Weight?loss Champion Faces High?Altitude Turbulence - AD HOC NEWS
Novo Nordisk Deepens Cell Therapy Push In Canada As Shares Screen Cheap - Sahm
Key facts: Novo Nordisk stock rises 9.12%; expands diabetes partnership; launches Ozempic ad campaign - TradingView
Is Oral Wegovy a Game Changer for Novo Nordisk? - Finviz
Novo Nordisk A/S-Spons ADR (NYSE:NVO) Demonstrates a Strong Dividend Profile Backed by High Profitability - Chartmill
Shorts Report: Can Novo Nordisk A s b Shares Adrhedged be the next market leader - baoquankhu1.vn
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - Finviz
Novo Nordisk (NVO) is "in a Battle," Says Jim Cramer - Finviz
Europe’s ADR Index Was Flat, But Single Stocks Were Not - Finimize
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? - Finviz
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? - Finviz
Looking At Novo Nordisk's Recent Unusual Options Activity - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged stock continue upward trendWeekly Loss Report & Daily Risk Controlled Trade Plans - Улправда
Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill - TechStock²
Novo Nordisk A/S (B Shares) ADRhedged (BATS:NVOH) Trading 0.4% Higher – What’s Next? - Defense World
CICC Initiates Coverage on Novo Nordisk with Outperform Rating and $73.50 Price Target for U.S. ADRBN - marketscreener.com
European ADRs Rose In US Trading As Chip And Pharma Led - Finimize
Will Novo Nordisk A s (b Shares) Adrhedged stock benefit from infrastructure spending2026 world cup usa national team semifinals star players high defensive line winner prediction tactical review - Улправда
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost - Sahm
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 - Finviz
Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)'s Weight Loss Pill - Finviz
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.78%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):